JP2022552378A5 - - Google Patents
Info
- Publication number
- JP2022552378A5 JP2022552378A5 JP2022522647A JP2022522647A JP2022552378A5 JP 2022552378 A5 JP2022552378 A5 JP 2022552378A5 JP 2022522647 A JP2022522647 A JP 2022522647A JP 2022522647 A JP2022522647 A JP 2022522647A JP 2022552378 A5 JP2022552378 A5 JP 2022552378A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- lnp composition
- lnp
- seq
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962915317P | 2019-10-15 | 2019-10-15 | |
| US62/915,317 | 2019-10-15 | ||
| US202063013139P | 2020-04-21 | 2020-04-21 | |
| US63/013,139 | 2020-04-21 | ||
| PCT/US2020/055852 WO2021076811A1 (en) | 2019-10-15 | 2020-10-15 | Mrnas encoding granulocyte-macrophage colony stimulating factor for treating parkinson's disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022552378A JP2022552378A (ja) | 2022-12-15 |
| JP2022552378A5 true JP2022552378A5 (enExample) | 2023-10-24 |
Family
ID=73198473
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022522647A Pending JP2022552378A (ja) | 2019-10-15 | 2020-10-15 | パーキンソン病を治療するための顆粒球マクロファージコロニー刺激因子をコードするｍＲＮＡ |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240123034A1 (enExample) |
| EP (1) | EP4045076A1 (enExample) |
| JP (1) | JP2022552378A (enExample) |
| AU (1) | AU2020366209A1 (enExample) |
| CA (1) | CA3158013A1 (enExample) |
| WO (1) | WO2021076811A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202214445D0 (en) * | 2022-09-30 | 2022-11-16 | Imp College Innovations Ltd | Gene therapy |
| WO2024240962A1 (en) * | 2023-05-25 | 2024-11-28 | Ethris Gmbh | Gm-csf-encoding nucleic acids, pharmaceutical compositions, methods and uses thereof |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8613481D0 (en) | 1986-06-04 | 1986-07-09 | Diatech Ltd | Translation of mrna |
| US5723332A (en) | 1993-11-26 | 1998-03-03 | British Technology Group Limited | Translational enhancer DNA |
| US5824497A (en) | 1995-02-10 | 1998-10-20 | Mcmaster University | High efficiency translation of mRNA molecules |
| EP2428570B1 (en) | 2001-09-28 | 2018-05-23 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Microrna molecules |
| US20040197312A1 (en) * | 2003-04-02 | 2004-10-07 | Marina Moskalenko | Cytokine-expressing cellular vaccine combinations |
| WO2005013901A2 (en) | 2003-07-31 | 2005-02-17 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding rnas |
| DE102005046490A1 (de) | 2005-09-28 | 2007-03-29 | Johannes-Gutenberg-Universität Mainz | Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen |
| EP2089049A4 (en) * | 2006-11-17 | 2011-11-16 | Biogen Idec Inc | SYSTEMIC ADMINISTRATION OF COLONIAL STIMULATING FACTORS TO TREAT AMYLOID ASSOCIATED DISEASES |
| EP2143794A1 (en) * | 2007-04-27 | 2010-01-13 | Kyushu University, National University Corporation | Viral vector for gene therapy |
| DK2205618T3 (en) | 2007-09-26 | 2017-02-20 | Intrexon Corp | SYNTHETIC 5 'NON-TRANSLATED REGIONS, EXPRESSION VECTORS AND PROCEDURES FOR INCREASING TRANSGENIC EXPRESSION |
| JP5539962B2 (ja) | 2008-04-25 | 2014-07-02 | ノースウェスタン、ユニバーシティ | コレステロールを隔離するのに適したナノ構造体 |
| PL215513B1 (pl) | 2008-06-06 | 2013-12-31 | Univ Warszawski | Nowe boranofosforanowe analogi dinukleotydów, ich zastosowanie, czasteczka RNA, sposób otrzymywania RNA oraz sposób otrzymywania peptydów lub bialka |
| KR20220038506A (ko) | 2009-06-10 | 2022-03-28 | 알닐람 파마슈티칼스 인코포레이티드 | 향상된 지질 조성물 |
| US9567398B2 (en) * | 2010-11-18 | 2017-02-14 | Merck Serono S.A. | Antibody with specificity for GM-CSF (II) |
| US9999673B2 (en) | 2011-01-11 | 2018-06-19 | Alnylam Pharmaceuticals, Inc. | PEGylated lipids and their use for drug delivery |
| WO2013151664A1 (en) * | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins |
| WO2014164253A1 (en) | 2013-03-09 | 2014-10-09 | Moderna Therapeutics, Inc. | Heterologous untranslated regions for mrna |
| WO2015130584A2 (en) | 2014-02-25 | 2015-09-03 | Merck Sharp & Dohme Corp. | Lipid nanoparticle vaccine adjuvants and antigen delivery systems |
| WO2016176330A1 (en) * | 2015-04-27 | 2016-11-03 | The Trustees Of The University Of Pennsylvania | Nucleoside-modified rna for inducing an adaptive immune response |
| DK3386484T3 (da) | 2015-12-10 | 2022-07-04 | Modernatx Inc | Sammensætninger og fremgangsmåder til afgivelse af terapeutiske midler |
| RS63625B1 (sr) | 2016-05-18 | 2022-10-31 | Modernatx Inc | Kombinacije irnk koje kodiraju imunomodulirajuće polipeptide i njihova upotreba |
| US20190314291A1 (en) * | 2018-01-30 | 2019-10-17 | Modernatx, Inc. | Compositions and methods for delivery of agents to immune cells |
-
2020
- 2020-10-15 CA CA3158013A patent/CA3158013A1/en active Pending
- 2020-10-15 US US17/768,514 patent/US20240123034A1/en not_active Abandoned
- 2020-10-15 JP JP2022522647A patent/JP2022552378A/ja active Pending
- 2020-10-15 EP EP20804059.2A patent/EP4045076A1/en not_active Withdrawn
- 2020-10-15 AU AU2020366209A patent/AU2020366209A1/en not_active Abandoned
- 2020-10-15 WO PCT/US2020/055852 patent/WO2021076811A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2026041749A5 (enExample) | ||
| US6653467B1 (en) | Medicament for treatment of Duchenne muscular dystrophy | |
| JP2022552371A5 (enExample) | ||
| Nakamura et al. | Controlled delivery of T-box21 small interfering RNA ameliorates autoimmune alopecia (Alopecia Areata) in a C3H/HeJ mouse model | |
| JP7710740B2 (ja) | ペプチド組成物 | |
| US20250064977A1 (en) | Nucleic Acid-Based Compositions and Methods for Treating Small Vessel Diseases | |
| TW201244724A (en) | Method of treating keloids or hypertrophic scars using antisense compounds targeting connective tissue growth factor (CTGF) | |
| TW202012628A (zh) | 用於帕金森氏症治療的組成物及方法 | |
| JP2021525707A5 (enExample) | ||
| JP6442027B2 (ja) | 活性成分の送達のための製剤 | |
| JP2024519451A5 (enExample) | ||
| EP2598525A2 (en) | Frataxin mutants | |
| JPH09509324A (ja) | 増殖阻止ホメオボックス遺伝子 | |
| JP2022553375A5 (enExample) | ||
| JPWO2006101173A1 (ja) | 核酸分子とコラーゲンの複合体微細粒子製剤 | |
| JP3877148B2 (ja) | 糖尿病性虚血性疾患遺伝子治療 | |
| JPWO2001032220A1 (ja) | 糖尿病性虚血性疾患遺伝子治療 | |
| ES2331835T3 (es) | Oligonucleotidos antisentido capaces de inhibir la formacion de tubos capilares. | |
| Zheng et al. | MiR-133a encapsulated in hyaluronic acid nanoparticles alleviates sepsis-induced cardiomyopathy by decreasing M1 macrophage polarization via the SOCS3/JAK/STAT3 pathway | |
| JP4526228B2 (ja) | ＲＮＡｉによる新規治療法および治療剤 | |
| WO2021167056A1 (ja) | Ｕｓａｇ－１を標的とするｒｎａ分子を含む歯の再生治療薬 | |
| CN114787355A (zh) | 具有血脑屏障穿透能力的肽-核酸复合物及包含该肽-核酸复合物的组合物 | |
| CN114517209B (zh) | 环状RNA circTTC3过表达腺相关病毒载体、腺相关病毒及其应用 | |
| CN120738343A (zh) | 一种锁核酸在制备治疗肺高压药物中的应用 | |
| TWI309570B (enExample) |